Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

eli_lilly

Lilly changes Alzheimer’s trial endpoint – shares fall

March 16, 2016
Research and Development Alzheimer's disease, Eli Lilly, solanezumab

Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …

News
adocia_lilly

Adocia and Lilly report positive early results for ultra-rapid insulin

March 15, 2016
Manufacturing and Production, Research and Development Adocia, BioChaperone Lispro, Eli Lilly, insulinm

Eli Lilly and development partner Adocia have announced today positive topline results from a Phase 1b clinical trial of ultra-rapid …

News
eli_lilly

Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials

March 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis

Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …

News
eli_lilly

CHMP recommends Lilly psoriasis drug for approval

February 29, 2016
Research and Development Eli Lilly, Taltz, psoriasis

Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

News
eli_lilly

European Commission approves Lilly’s Portrazza for NSCLC

February 24, 2016
Research and Development Eli Lilly, Portrazza

The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …

News
eli_lilly

Lilly suffers damaging Alimta patent blow

February 15, 2016
Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed

Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …

News
fda

Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Feature
Jardiance

FDA reviews Jardiance as cardiovascular diabetes treatment

January 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …

News
eli_lilly_logo

Lilly awaits FDA review of new arthritis treatment

January 20, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis

Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …

News
Lilly building

Eli Lilly predicts revenue growth in 2016

January 5, 2016
Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales

Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …

News
FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …

News
juan_luciano

Juan Luciano appointed to Eli Lilly board

December 16, 2015
Medical Communications Eli Lilly

The board of directors of Eli Lilly has elected Juan Luciano as a new member, effective February 1 2016. Luciano …

Appointment
zometa

Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015
Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …

News
keytruda

Lilly and Merck extend immuno-oncology collaboration

November 20, 2015
Medical Communications, Research and Development Eli Lilly, Merck

Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024